Seattle, WA – YouScript and Elsevier are collaborating to bring individualized, relevant drug and dose optimization guidance to providers, pharmacists and patients wherever medication decisions are made.
On February 2, 2017, Harding University published a randomized controlled trial in PLOS One in high-risk polypharmacy patients to incorporate pharmacogenetic data and YouScript’s clinical decision support system and compare results to a standard drug information system. The study showed a reduction in readmissions by 52 percent (p=0.007) and ER visits by 42 percent (p=0.045). This data validates a previous study (IMPACT) published by YouScript and the University of Utah in 2015.
Current clinical decision support tools and drug interaction software use drug safety alerts that occur too often, leading physicians to alert fatigue. Alert fatigue is a major patient safety issue as it can cause providers to miss or ignore significant warnings, putting the patient in danger. To address this, YouScript’s precision prescribing system combines alerts into top-level, clinically actionable items to reduce fatigue.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions and deliver better care. YouScript has licensed Elsevier’s Gold Standard Drug Database, which combines modern technical architecture with current, accurate content and built-in human logic for superior decision support.
“By combining the vast drug information database from Elsevier with YouScript’s technology, we are listening to what providers have requested,” said YouScript CEO Kristine Ashcraft “and surfacing the safest, most effective medication choices the current evidence allows for right in the prescribing workflow.”
Traditional drug interaction systems monitor drug-drug and drug-gene interactions in a basic one-to-one, binary manner. YouScript’s algorithms combine traditional binary interactions with cumulative drug-drug-drug and drug-drug-gene interactions, capturing 34% more significant interactions. With this increased rate of proactive detection, YouScript combines precise alerts into targeted warnings, providing predictive “auditioning” of alternative medications and at-a-glance clinical management options.
“We are excited to collaborate with YouScript on its efforts to bring the benefits of precision medicine to bear,” said Kay Morgan, Vice President, Drug Products & Industry Standards, Elsevier. “We are pleased to be able to provide YouScript’s user-interface, analytics and algorithms with Elsevier’s extensive drug database to help YouScript bring individualized, relevant drug and dose optimization alerts to providers, pharmacists and patients.
###
About YouScript
Based on fifteen years of technology development that makes precision prescribing possible, Seattle-based YouScript was founded in 2016 after spinning out of Genelex. The YouScript clinical decision support tool is the only medication management system available that assesses the cumulative effect of a patient drug regimen and unique pharmacogenomic results. Based on over 14,000 curated references and product inserts, YouScript uses comprehensive predictive analytics to interpret and provide an at-a-glance summary of the complex web of genetics, medications, over-the-counters, herbals, and other factors impacting drug safety and response; identifying at risk patients for testing and offering ranked alternatives with reduced interaction risk whenever an adverse interaction risk is found.
For more information, visit: www.youscript.com or HIMSS Booth #823.
About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey — and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com
—
Press Contacts:
YouScript:
Jennifer Hayes
206-826-1921
[email protected]
Elsevier:
Christopher Capot
Director, Corporate Communications
+1 917 704 5174 (mobile)
[email protected]
